New hope for tough breast cancer: experimental drug takes on chemo
NCT ID NCT06382142
First seen Nov 17, 2025 · Last updated Apr 23, 2026 · Updated 23 times
Summary
This study tests a new drug called BL-B01D1 against standard chemotherapy for people with advanced triple-negative breast cancer that has stopped responding to taxane chemotherapy. About 418 adults will take part. The goal is to see if BL-B01D1 can slow cancer growth and help people live longer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRIPLE NEGATIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China
Conditions
Explore the condition pages connected to this study.